Results 81 to 90 of about 136,173 (262)

Cardiovascular and neuropsychiatric outcomes with PCSK9 inhibitors in atherosclerotic cardiovascular disease: A retrospective cohort study

British Journal of Clinical Pharmacology, EarlyView.
Study design and main findings. After 1:1 propensity score matching, 60 885 PCSK9 inhibitor users and 60 885 statin‐only users with ASCVD were compared. Kaplan–Meier curves show 12‐month cumulative event‐free survival for MACE, psychiatric disease, and neurodegenerative disease.
Tianshu Gu, Yang Chen, Nan Zhang, Uazman Alam, Riccardo Proietti, Tong Liu, Kang‐Yin Chen, Gregory Y. H. Lip   +7 more
wiley   +1 more source

Candesartan inhibits inflammation through an angiotensin II type 1 receptor independent way in human embryonic kidney epithelial cells

Anais da Academia Brasileira de Ciências, 2019
: Besides stimulating vasoconstriction, Angiotensin II is also well known in inducing reactive oxygen species and promoting inflammatory phenotype switch via its type 1 receptor.
YING YU, HAIFENG JIANG, YANGYANG NIU, XIAOQIN ZHANG, YINGYING ZHANG, XI LIU, TAO QI, CHEN YU   +7 more
doaj   +1 more source

Angiotensin II promotes melanogenesis via angiotensin II type 1 receptors in human melanocytes

Molecular Medicine Reports, 2012
Angiotensin II (AngII) is a hormone with long-established cardiovascular actions. Previous studies have revealed an additional role for AngII in the regulation of cutaneous wound healing. To evaluate the association between AngII and abnormal pigmentation of cutaneous wound healing, the present study used human melanocytes to investigate the effects of
Li-Hong, Liu, Xin, Fan, Hai-Tao, Li, Xu-Xi, An, Rong-Ya, Yang   +4 more
openaire   +3 more sources

Semaglutide vs. liraglutide and incidence of diabetes and cardiovascular disease: A target trial emulation using real‐world data

British Journal of Clinical Pharmacology, EarlyView.
Aims The glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) semaglutide and liraglutide are approved for chronic weight management. Both drugs also have favourable effects on the risk of developing diabetes and cardiovascular disease (CVD) compared with placebo, but their comparative effectiveness for these outcomes is unclear.
Ethan J. Cannon, Wendy Wang, Faye L. Norby, Rob F. Walker, Shalini Kulasingam, Lisa S. Chow, Joel F. Farley, Pamela L. Lutsey   +7 more
wiley   +1 more source

Hypertension in obesity: A focus on individualized pharmacotherapy and the role of body composition, on behalf of the European Society of Hypertension Working Group on Diabetes and Metabolic Risk Factors and Working Group on Lifestyle, Cardiovascular Pharmacotherapy and Adherence

British Journal of Clinical Pharmacology, EarlyView.
Hypertension in obesity represents a major global health challenge, closely linked to the global epidemics of obesity, type 2 diabetes and metabolic dysfunction. Excess adiposity contributes to elevated blood pressure through multiple, interrelated mechanisms, including activation of the renin–angiotensin–aldosterone system, sympathetic nervous system ...
Christina Antza, Andrej Belancic, Jens Jordan, Alberto Esteban, Anna Oliveras, Ryan McNally, Panagiota Anyfanti, Jorie Versmissen, María S. Fernández‐Alfonso, Vasilios Kotsis, Thomas Weber, Alexandre Persu, Reinhold Kreutz   +12 more
wiley   +1 more source

Acute Urinary Bladder Distension Triggers ICAM-1-mediated Renal Oxidative Injury via the Norepinephrine–renin–angiotensin II System in Rats

Journal of the Formosan Medical Association, 2009
Acute urinary bladder distension (AUBD) can activate bladder mechanical afferent and renal sympathetic nerves, which contributes to renal vasoconstriction.
Show-Shing Chen, Wang-Chuan Chen, Satoshi Hayakawa, Ping-Chia Li, Chiang-Ting Chien   +4 more
doaj   +1 more source

Bridging the translational gap in clinical nanomedicine: From rational design to clinical reality

BMEMat, EarlyView.
Nanotechnology offers a multi‐faceted approach to modern healthcare, encompassing high‐sensitivity diagnostic imaging, innovative vaccine delivery, and targeted therapeutics. This review explores how these nanomedicine applications address critical challenges in cancer recurrence and the treatment of neurologic and respiratory diseases to combat rising
Ahmed H. Ghonaim, Marwa Ahmed El‐Naka, Wedad M. Nageeb, Atta Ullah Khan, Noura M. Seleem, Aliaa Abdelghafar, Doaa Zamel, Yang Liu, Qigai He, Wentao Li   +9 more
wiley   +1 more source

Advances in the Renin-Angiotensin-Aldosterone System: Relevance to Diabetic Nephropathy

The Scientific World Journal, 2008
Hypertension is now recognized as a key contributory factor to the development and progression of kidney disease in both type 1 and type 2 diabetes. The renin angiotensin system (RAS) and its effector molecule angiotensin II, in particular, have a range ...
Audrey Koitka, Christos Tikellis
doaj   +1 more source

Evaluation of Treatment Response of Calcified Nodules and Nodular Calcified Lesions Using Mean Density on Coronary Computed Tomography Angiography

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Calcified nodules (CN) and nodular calcifications (NC) present significant challenges during percutaneous coronary intervention (PCI) because of their protruding morphology and high rigidity, which often result in inadequate stent expansion and suboptimal procedural outcomes.
Akito Setoguchi, Keita Iyama, Ryosuke Iwasaki, Saburo Kusumoto, Yoshiyuki Doi, Tatsuya Nunohiro, Masayoshi Takeno, Koji Maemura   +7 more
wiley   +1 more source

The Effect of Endogenous Angiotensin II on Alveolar Fluid Clearance in Rats with Acute Lung Injury

Canadian Respiratory Journal, 2012
BACKGROUND: In acute lung injury (ALI), angiotensin II (Ang II) plays a vital role in the stimulation of pulmonary permeability edema formation through the angiotensin type 1 (AT1) receptor.
Jia Deng, Dao-xin Wang, Wang Deng, Chang-yi Li, Jin Tong   +4 more
doaj   +1 more source